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CObjectives: We evaluated the cost-effectiveness of universal mass
vaccination (UMV) against influenza compared with a targeted vaccine
program (TVP) for selected age and risk groups in the United States.
Methods: Wemodeled costs and outcomes of seasonal influenza with
UMV and TVP, taking a societal perspective. The US population was
stratified tomodel age-specific ( 5, 5–17, 18–49, 50–64, and 65 years)
vaccine coverage and efficacy. Probability of influenza-related illness
(ILI) and complications, health-care utilization, costs, and survival
were estimated. For a season’s intervention, ILI cases in that year, life-
time costs (2008 US$), and quality-adjusted life years (QALYs) lost (both
discounted at 3% per annum) were calculated for each policy and used
to derive incremental cost-effectiveness ratios. A range of sensitivity
and alternative-scenario analyses were conducted. Results: In base-
case analyses, TVP resulted in 63 million ILI cases, 859,000 QALYs lost,
and $114.5 billion in direct and indirect costs; corresponding estimates O
t Ro
al So
oi:10.1016/j.jval.2011.03.005or UMV were 61 million cases, 825,000 QALYs lost, and $111.4 billion.
MV was therefore estimated to dominate TVP, saving $3.1 billion and
4,000 QALYs. In probabilistic sensitivity analyses, UMVwas dominant
n 82% and dominated in 0% of iterations. In alternative-scenario anal-
ses, UMV dominated TVP when lower estimates of vaccine coverage
ere used. Lower estimates of ILI risk among unvaccinated, vaccine
ffectiveness, and risk of complications resulted in ICERs of $2800,
8100, and $15,900 per QALY gained, respectively, for UMV compared
ith TVP. Conclusions: UMV against seasonal influenza is cost saving
n the United States under reasonable assumptions for coverage, cost,
nd efficacy.
eywords: cost-effectiveness analysis, influenza vaccination.
opyright © 2011, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Influenza is a highly contagious, airborne, viral infection that ac-
counts for considerable morbidity, mortality, and economic costs
in the United States [1]. It is estimated that approximately 36,000
annual deaths can be attributed to seasonal influenza, resulting in
more than 600,000 life-years lost [2,3]. Direct medical costs asso-
ciated with influenza total approximately $10 billion per year in
2003 US dollars [3].
Vaccination is an effective preventive measure against sea-
sonal influenza, reducing risk of contracting the virus by 50% to
75% [4–6]. Until recently, the Centers for Disease Control and Pre-
vention guidelines recommended vaccination for children aged 6
months until their fifth birthday, pregnantwomen, adults 50 years
of age and older, persons of any age with certain chronic medical
conditions that impose an elevated risk of influenza complications
(“high risk” individuals), residents of nursing homes and other
long-term care facilities, and household contacts of and caregivers
for high risk individuals [7].
In 2008, the Advisory Committee on Immunization Practices
recommended to expand vaccination to all children up to age 18
years, citing evidence of benefits and cost-effectiveness of in-
creased vaccination in this age group [7]. In addition to its direct
effect, several studies demonstrated a substantial beneficial indi-
* Address correspondence to: Karen Clements, I3 Innovus, 10 Cabo
E-mail: karen.clements@i3innovus.com.
098-3015/$36.00 – see front matter Copyright © 2011, Internation
ublished by Elsevier Inc.rect effect of vaccination among unvaccinated contacts of those
whowere vaccinated, due to reduced virus transmission (so-called
herd immunity) [8–10]. Furthermore, universal vaccination of chil-
dren was demonstrated to be cost-saving or cost-effective [11,12].
In August 2010, the Advisory Committee on Immunization
Practices posted a recommendation to expand vaccination to in-
clude all adults, stating that all persons aged 6 months and older
should be vaccinated annually [13]. Several arguments have been
advanced in favor of such a recommendation [14]. The first is the
opportunity to reduce the substantial public health burden of in-
fluenza. The second is that simplification is desirable, as the cur-
rent piecemeal approach has not achieved optimal coverage even
among target groups. Third, expanded use of seasonal vaccination
would stimulate increased production capacity that could be di-
verted to pandemic vaccine, assisting the goal of pandemic pre-
paredness. Reports from Ontario, Canada, where universal vacci-
nation for all ages was implemented in 2000, demonstrate
decreased influenza-related mortality and health care use com-
pared to other provinces in which universal vaccination was not
implemented [15]. Moreover, the program was found to be cost-
effective [16]. To date the cost-effectiveness of universal vaccina-
tion in the United States has not been demonstrated. The purpose
of this study was to evaluate the cost-effectiveness of a recom-
mendation of universal vaccination of all persons in the United
States.
ad Suite 304, Medford MA 02155, USA.
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Overview
We adapted a decision tree model of seasonal influenza vaccina-
tion reported by Aballéa et al. [17] to examine costs and outcomes
associated with implementing a recommendation of universal
mass vaccination (UMV) in the United States compared with the
2008 recommendations of targeting specific age and risk groups, a
targeted vaccine policy (TVP). Themodelwas composed of five age-
groupmodules: younger than 5 years, 5 to 17 years, 18 to 49 years, 50
to 64 years, and 65 years and older. The model used the case defini-
tion of influenza-like illness (ILI), including cases of both true influ-
enza and noninfluenza illness, because data regarding treatment
and outcomes aremore readily available for ILI than for serologically
confirmed influenza. Because influenza vaccination does not reduce
noninfluenza illness, estimates of vaccine efficacy against influenza
were adjusted to reflect effectiveness against ILI.
In base-case analyses, we evaluated only the direct effect of vac-
cination; that is, the reduction in ILI among those vaccinated. Indi-
rect effects, that is, the reduction in ILI among unvaccinated persons
due to lower disease transmission with increased vaccination (so-
called herd immunity) were incorporated in alternative-scenario
analyses. Themodelwas used to project a range of clinical outcomes
and estimate the cost-effectiveness of UMV versus TVP in terms of
the incremental cost per quality-adjusted life year (QALY) gained. All
analyses were conducted from a societal perspective. The time hori-
zon for intervention was one year; costs and QALYs resulting from
outcomes occurring during the intervention period were assessed
over individuals’ lifetimes. Themodelwas programmed inMicrosoft
Excel version 5.1.2600 Service Pack 3 (2003, Microsoft Corp., Red-
mond, WA).
Model structure
Thedecision tree structure ispresented inFigures 1and2. For eachof
the two strategies, identical pathwayswere defined representing the
chance events and outcomes contingent on the chosen strategy. The
model includes branching for vaccination policy, risk status, receipt
of vaccination, development of ILI and associated complications,
health care utilization, and survival. Each age group was analyzed
separately as a cohort consisting of the total number of age-specific
members of the US population. As described above, each age group
Fig. 1 – Model structure Part 1: policy and implementation. Nowas categorized by risk for developing complications from influenza.For the three adult age cohorts, the high-risk group consisted of per-
sons with respiratory disease (including asthma and chronic ob-
structivepulmonarydisease), cardiovasculardisease (including isch-
emic heart disease and congestive heart failure), diabetes mellitus,
Parkinson’s disease, chronic renal disease, or immunosuppression
due to disease, treatment, or human immunodeficiency virus [7]. For
the two childhood cohorts, the high-risk group was limited to chil-
drenwith asthma because the prevalence of the other high-risk con-
ditions among children is small.
The model allowed vaccine coverage to be defined by both age
and risk group for each strategy. Although there is no difference
between UMV and TVP recommendations for children younger
than 5 years and 5 to 17 years, high risk adults ages 18 to 49 years,
and adults 50 years and older, it was expected that UMV would
stimulate increased uptake in these groups.
After the choice of vaccination, patients could develop ILI or
stay healthy. Patients with ILI could seek treatment or not, receive
an antiviral or not, and develop a complication or not. An ILI com-
plication was defined as prescription of antibiotics or inpatient
hospitalization occurring within 2 weeks of ILI onset among pedi-
atric patients [18], and pneumonia, other respiratory disease,
and/or cardiovascular complications among adults [19]. The com-
plications could require either outpatient or inpatient hospital
care, and could be fatal or not.
Model outcomes
The model calculated the total costs associated with each policy,
including the cost of vaccination, (acquisition and administration
costs), outpatient care (ILI treatment and treatment of complica-
tions), cost of antiviral treatment, inpatient treatment for complica-
tions, and lost productivity due to acute disease andmortality.
Clinical outcomes estimated by the model included ILI cases,
hospitalizations, deaths, and survival time, measured both as life
years and QALYs. Transient reductions in quality of life due to
acute disease were not considered, nor were adverse effects of
vaccination, which are generally local reactions with negligible
influence on costs or quality of life [7].
Data sources
Model parameters were estimated separately for each age group.
Base-case model estimates, standard errors, and data sources are
peating parts of the tree, or “subtrees,” are omitted for clarity.presented in Tables 1 through 3.
802 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 8 0 0 – 8 1 1The proportion at high risk of complications and current vac-
cine coverage in each age- and risk group were obtained from
national survey data [7,20–21]. In the absence of data specific to
the United States, estimated coveragewith UMVwas derived from
published reports of changes in vaccination coverage after imple-
mentation of a policy of universal vaccination in Ontario, Canada
[15]. The estimated percentage reduction in unvaccinated persons
after policy implementation in Canadawas applied to current vac-
cination coverage in the United States. For example, among low
risk adults, the proportion that remained unvaccinated decreased
18.5% after implementation of UMV in Ontario, so we assumed a
similar decrease would occur in the United States. Change in vac-
cination among children was not reported; we therefore assumed
that the reduction in the percentage of unvaccinated children was
similar to that in adults.
Because studies of vaccine effectiveness against ILI are scarce,
estimates of the reduction in ILI among vaccinated individuals
were derived from published age-specific estimates of developing
influenza illness among unvaccinated persons andmeta-analyses
of vaccine effectiveness against influenza [4–5,22]. For analyses
that included the indirect effect of vaccination, the probability of
ILI among unvaccinated persons in the UMV arm was lowered
from the base-case value. Estimates of the reduction in ILI among
unvaccinated due to indirect effect were derived from a published
simulation model of influenza transmission that predicted the
number of influenza cases in the United States among persons
ages 0 to 18 years, 19 to 64 years, and 65 years and older, with 5%,
20%, 40%, 60%, and 80% child vaccine coverage [9]. Details of the
methodology are described in the Appendix found at doi:10.1016/
Fig. 2 – Model structure Part 2:j.jval.2011.03.005.The percentage of patients who develop ILI complications re-
quiring inpatient or outpatient carewas estimated frompublished
claims analyses of inpatient and outpatient health care utilization
associated with ILI [12,18–19,22–23]. Mortality risk following hos-
pitalization was derived from published estimates [2,24].
Life-years lost due to ILI were estimated by summing life ex-
pectancy of fatal cases. QALYs lost were estimated by applying
age-specific utility estimates to the expected life expectancy of
fatal cases. The utilitieswere derived from the published literature
[25]; life expectancy data were obtained from the National Center
for Health Statistics [26].
The cost of the influenza vaccine was estimated from national
average prices listed on the Centers for Disease Control and Pre-
vention vaccine Web site, assuming that 68% of vaccinated chil-
dren younger than age 8 years received two doses and the rest
received one dose [27]. Costs associated with vaccine administra-
tion and the cost of a physician visit for treatment of ILI was esti-
mated from the 2008 Physicians’ Fee and Coding Guide[28]. The costs
of antiviral drugs used to treat ILI were estimated from national
average wholesale prices published in the 2008 Drug Topics Red
Book[29].Medical costs forpatientswithcomplications requiringout-
patient and inpatient care were estimated from published claims
analysis of costs associated with influenza complications [3].
The average number of workdays missed due to ILI was esti-
mated based ondata from thepublished literature [3]. Lostworkdays
were assigned to all persons with ILI, whether or not they partici-
pated in the workforce. It was assumed that adults not participating
in the workforce worked inside the home, thus incurring lost work-
days, and thatworkdayswere lost by caregivers in caring for ILI cases
enza-like illness (ILI) subtree.Influamong children. Average daily wages were obtained from the US
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803V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 8 0 0 – 8 1 1Bureau of Labor Statistics [30]. To calculate lost productivity due to
premature death, average yearly wages and workforce participation
were also obtained from the US Bureau of Labor Statistics [30].
Analyses
Expected population costs and clinical outcomes were calculated
by running the model for each age group and summing over age
groups. Costs by category and a range of clinical outcomes were
reported in disaggregated form for each strategy. Incremental val-
ues were reported, representing the budgetary and healthcare im-
pact of UMV. Incremental cost-effectiveness ratios (ICERs) were
calculated for the aggregate US population by dividing the differ-
ence between the compared strategies in expected costs by the
difference in expected numbers of QALYs. UMV was reported to
dominate TVP when UMV was less costly and more effective than
TVP. The base case conservatively evaluated only the direct effects
of vaccination, ignoring potential indirect effects. The estimates of
total cost in the economic analyses did not include costs associ-
ated with productivity changes, consistent with US Panel on Cost-
Effectiveness recommendations [31].
Where underlying model assumptions were uncertain or year-
o-year variation in the estimate existed, scenario analyses were
arried out to test the effect of alternative plausible assumptions.
ive alternative scenarios were evaluated:
Inclusion of indirect effect. The risk of ILI among unvaccinated
ersons in each age group in the UMV arm was reduced as pre-
icted by the Weycker et al. model, described in the Appendix
Table 1 – Model inputs: probability of vaccination and ILI.
Variable Estimate
High risk Low risk
Probability of vaccination, TVP
5 y 0.49 0.31
5–17 y 0.33 0.18
18–49 y 0.26 0.15
50–64 y 0.46 0.32
65 y 0.71 0.61
Probability of vaccination, UMV
5 y 0.62 0.44
5–17 y 0.47 0.30
18–49 y 0.45 0.31
50–64 y 0.62 0.48
65 y 0.83 0.71
Probability of ILI, unvaccinated, UMV
& TVP (direct effect only)
5 y 0.40
5–17 y 0.20
18–49 y 0.20
50–64 y 0.20
65 y 0.31
Probability of ILI, unvaccinated, UMV
(direct  indirect effect)
5 y 0.24
5–17 y 0.12
18–49 y 0.16
50–64 y 0.16
65 y 0.26
ILI, influenza-like illness; TPV, targeted vaccine program; UMV, univeound at doi:10.1016/j.jval.2011.03.005.Reduced ILI risk, unvaccinated. Because substantial year-to-year
variation exists in the risk of ILI, we evaluated a scenario where
risk of ILI in each age group was at the low end of inter-seasonal
variation as measured by year-to-year variation in outpatient vis-
its for influenza in the United States. In this scenario we assumed
a 24% reduction in ILI risk from the base-case estimate in both the
TVP and UMV arms, in each age group [32].
Lower vaccine coverage with UMV. Because it is unknown how
MV will affect actual coverage, we evaluated a less optimistic sce-
ario in which we assumed that the increase in vaccine coverage
fter UMV is only 50% that assumed in the base case. For example,
mong children younger than 5 years of age, the base-case estimate
f coverage for high-risk children in theUMVarmwas 61.9%, a 26.8%
ncrease from coverage in the TVP arm. The alternative estimate is
5.5%, a 13.4% increase from TVP.
Reduced complications, no doctor visit. The base-case assump-
ion that patients who did not initially seek treatment for ILI had
he same risk of complications as those who did seek treatment
ay overestimate the risk of ILI complications, because these pa-
ients may have had milder illness and lower probability of com-
lications. In this scenario we assumed the risk of complications
n this group was 0%.
Reduced vaccine effectiveness. Vaccine effectiveness may vary
substantially from year to year due to varying match between cir-
culating virus and vaccine composition [33]. Clinical trials that
Standard error Reference
High risk Low risk
0.05 0.03 NHIS 2003-2007
0.02 0.01 NHIS 2003-2007
0.01 0.004 NHIS 2003-2007
0.01 0.01 NHIS 2003-2007
0.07 0.06 NHIS 2003-2007
N/A N/A Kwong, 2007
N/A N/A Kwong, 2007
N/A N/A Kwong, 2007
N/A N/A Kwong, 2007
N/A N/A Kwong, 2007
0.03 Prosser 2007, Nichol 2008, Vu 2002
0.02 Prosser 2007, Nichol 2008, Vu 2002
0.01 Prosser 2007, Nichol 2008, Vu 2002
0.01 Prosser 2007, Nichol 2008, Vu 2002
0.03 Prosser 2007, Nichol 2008, Vu 2002
0.03 Prosser 2007, Nichol 2008, Vu
2002, Weycker 2005
0.02 Prosser 2007, Nichol 2008, Vu
2002, Weycker 2005
0.01 Prosser 2007, Nichol 2008, Vu
2002, Weycker 2005
0.01 Prosser 2007, Nichol 2008, Vu
2002, Weycker 2005
0.03 Prosser 2007, Nichol 2008, Vu
2002, Weycker 2005
mass vaccination.were conducted during years of mismatch between circulating
804 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 8 0 0 – 8 1 1Table 2 – Model inputs: Vaccine efficacy, ILI treatment, and complications of ILI.
Variable Estimate Standard error Reference
High risk Low risk High risk Low risk
% reduction in ILI among vaccinated
5 y 36.0 0.06 Prosser 2007, Nichol 2008, Vu 2002
5–17 y 36.0 0.04 Prosser 2007, Nichol 2008, Vu 2002
18–49 y 17.5 0.03 Prosser 2007, Nichol 2008, Vu 2002
50–64 y 17.5 0.03 Prosser 2007, Nichol 2008, Vu 2002
65 y 35.0 0.05 Prosser 2007, Nichol 2008, Vu 2002
Probability of physician visit, ILI
5 y 0.91 0.46 0.09 0.05 Prosser 2007, Molinari 2007
5–17 y 0.64 0.32 0.06 0.03 Prosser 2007, Molinari 2007
18–49 y 0.63 0.31 0.06 0.03 Prosser 2007, Molinari 2007
50–64 y 0.63 0.31 0.06 0.03 Prosser 2007, Molinari 2007
65 y 0.82 0.60 0.08 0.06 Prosser 2007, Molinari 2007
Probability of outpatient complication, ILI, no
antiviral
5 y 0.44 0.27 0.01 0.004 Irwin 2001, Barr 2007, Prosser 2006,
Nordstrom, 2007, Prosser 2007
5–17 y 0.43 0.27 0.01 0.004 Irwin 2001, Barr 2007, Prosser 2006,
Nordstrom, 2007, Prosser 2007
18–49 y 0.30 0.19 0.01 0.01 Irwin 2001, Barr 2007, Prosser 2006,
Nordstrom, 2007, Prosser 2007
50–64 y 0.27 0.17 0.02 0.01 Irwin 2001, Barr 2007, Prosser 2006,
Nordstrom, 2007, Prosser 2007
65 y 0.43 0.27 0.04 0.03 Irwin 2001, Barr 2007, Prosser 2006,
Nordstrom, 2007, Prosser 2007
Probability of inpatient complication, ILI, no
antiviral
5 y 0.02 0.004 0.00 0.0004 Irwin 2001, Barr 2007, Prosser 2006,
Nordstrom, 2007, Prosser 2007
5–17 y 0.01 0.003 0.001 0.0004 Irwin 2001, Barr 2007, Prosser 2006,
Nordstrom, 2007, Prosser 2007
18–49 y 0.03 0.007 0.01 0.001 Irwin 2001, Barr 2007, Prosser 2006,
Nordstrom, 2007, Prosser 2007
50–64 y 0.08 0.02 0.01 0.001 Irwin 2001, Barr 2007, Prosser 2006,
Nordstrom, 2007, Prosser 2007
65 y 0.14 0.03 0.02 0.004 Irwin 2001, Barr 2007, Prosser 2006,
Nordstrom, 2007, Prosser 2007
Probability of antiviral treatment
5 y 0.17 Barr 2007, Nordstrom 2005, MMWR 2008
5–17 y 0.21 0.02 Barr 2007, Nordstrom 2005, MMWR 2008
18–49 y 0.17 0.02 Barr 2007, Nordstrom 2005, MMWR 2008
50–64 y 0.17 0.02 Barr 2007, Nordstrom 2005, MMWR 2008
65 y 0.17 0.02 Barr 2007, Nordstrom 2005, MMWR 2008
Probability of outpatient complication, ILI,
antiviral
5 y 0.25 N/A Irwin 2001, Barr 2007, Nordstrom 2007
5–17 y 0.14 N/A Irwin 2001, Barr 2007, Nordstrom 2007
18–49 y 0.10 N/A Irwin 2001, Barr 2007, Nordstrom 2007
50–64 y 0.10 N/A Irwin 2001, Barr 2007, Nordstrom 2007
65 y 0.10 N/A Irwin 2001, Barr 2007, Nordstrom 2007
Probability of inpatient complications, ILI, antiviral
5 y 0.28 N/A Irwin 2001, Barr 2007, Nordstrom 2007
5–17 y 0.17 N/A Irwin 2001, Barr 2007, Nordstrom 2007
18–49 y 0.27 N/A Irwin 2001, Barr 2007, Nordstrom 2007
50–64 y 0.27 N/A Irwin 2001, Barr 2007, Nordstrom 2007
65 y 0.27 N/A Irwin 2001, Barr 2007, Nordstrom 2007
Probability of death, inpatient complication
5 y 0.004 0.0004 Thompson 2003, 2004
5–17 y 0.02 0.001 Thompson 2003, 2004
18–49 y 0.02 0.001 Thompson 2003, 2004
50–64 y 0.07 0.04 Thompson 2003, 2004
65 y 0.16 0.01 Thompson 2003, 2004
Probability of death, outpatient complication
All ages 0 NA AssumptionILI, influenza-like illness.
805V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 8 0 0 – 8 1 1virus and vaccine composition were used to estimate the low
boundary of vaccine effectiveness, 30% lower than the base case
[7,34–35].
Although it was assumed that the first alternative scenario
would result in more favorable cost-effectiveness results than the
Table 3 – Model inputs: Cost of vaccination and ILI treatme
Cost
High risk
Influenza costs
Physician visit, ILI treatment
Antiviral medication
5 y
5–17 y
18–49 y
50–64 y
65 y
Physician visit, outpatient complication
5 y
5–17 y
18–49 y
50–64 y
65 y
Hospitalization, inpatient visit
5 y
5–17 y
18–49 y
50–64 y
65 y
Cost of lost workday
Lost work days
No complication
5 y
5–17 y
18–49 y
50–64 y
65 y
Inpatient complication
5 y 31
5–17 y 23
18–49 y 21
50–64 y 24
65 y 18
Outpatient complication
5 y 6
5–17 y 4
18–49 y 2
50–64 y 4
65 y 7
Vaccination costs
Vaccination
5 y
5–17 y
18–49 y
50–64 y
65 y
Administration
5 y
5–17 y
18–49 y
50–64 y
65 y
ILI, influenza-like illness.base case, the other alternative scenarios were chosen becausethey were at the end of the range of plausible values that would
result in the least favorable cost-effectiveness results, to gain in-
sights into the lower bounds of cost-effectiveness.
For variables not evaluated in alternative analyses, a determin-
istic sensitivity analysis was conducted to test the robustness of
case ($) Reference
Low risk
63 Phys Fee and Coding Guide 2008
37 Red Book 2008
66 Red Book 2008
75 Red Book 2008
75 Red Book 2008
75 Red Book 2008
254 Molinari 2007
207 Molinari 2007
309 Molinari 2007
497 Molinari 2007
487 Molinari 2007
,515 Molinari 2007
,896 Molinari 2007
,317 Molinari 2007
,043 Molinari 2007
,864 Molinari 2007
144 Bureau of Labor Statistics
1 Molinari 2007
0.5 Molinari 2007
0.5 Molinari 2007
0.5 Molinari 2007
1 Molinari 2007
8 Molinari 2007
9 Molinari 2007
12 Molinari 2007
13 Molinari 2007
13 Molinari 2007
1 Molinari 2007
1 Molinari 2007
1 Molinari 2007
2 Molinari 2007
3 Molinari 2007
19 CDC Vaccine Price List 2009
14 CDC Vaccine Price List 2009
9 CDC Vaccine Price List 2009
9 CDC Vaccine Price List 2009
9 CDC Vaccine Price List 2009
31 Phys Fee and Coding Guide 2008
31 Phys Fee and Coding Guide 2008
23 Phys Fee and Coding Guide 2008
23 Phys Fee and Coding Guide 2008
23 Phys Fee and Coding Guide 2008nt.
Base
30
28
39
44
19cost-effectiveness results to changes in key parameters. This was
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806 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 8 0 0 – 8 1 1done by varying parameters one at a time through 75%and 125%of
the base-case value and calculating the effect on cost-effective-
ness and budgetary effects in the usualway. Vaccination coverage,
probabilities of receiving ILI treatment, developing complications
and mortality, and cost of ILI treatment and complications were
evaluated in the deterministic sensitivity analysis.
To assess the influence of uncertainty in the precision of pa-
rameter estimates, a probabilistic sensitivity analysis was per-
formed [36]. Parameters were expressed as probability distribu-
ions around their estimatedmeans and aMonte Carlo simulation
as carried out, in which values were drawn at random with re-
lacement in 1000 iterations, yielding a distribution of results. Pa-
ameters handled in this fashion included vaccination coverage,
robabilities of receiving ILI treatment, developing complications
nd mortality, and the cost of ILI treatment and complications.
istributions were derived from the published literature and ex-
ert judgment. For each of these parameters, it was assumed that
ge-specific estimates were independent from the estimates in
he other age groups. The probabilistic sensitivity analyses were
erformed for the base case and alternative analyses for the over-
ll US population. The percentage of iterations in which UMV
ominated TVP is reported. The results are also presented as the
etmonetary benefit, by rescaling QALYs into dollars according to
range of values that decision makers might be willing to pay for
marginal QALY. A strategy with a positive net benefit value at a
iven valuation of a QALY is considered to be cost-effective. Net
enefit curves present the mean, 95% confidence intervals, and
nterquartile range for the net benefit at each QALY threshold
evel.
Results
Outcomes
Estimated health outcomes under UMV and TVP by age are pre-
sented in Table 4. In the population as a whole, TVP projects an
annual US total of 63 million ILI cases, leading to 1.4 million hos-
pitalizations and nearly 148,000 deaths per year, resulting inmore
than 1 million life-years lost. Almost 43% of cases occur among
adults aged 18 to 49 years, whereasmore than 81% of deaths occur
among adults aged 65 years and older. UMV results in fewer ad-
verse outcomes in all age groups. The projected reduction in ILI
cases is highest among adults aged 18 to 49 years (782,000 cases),
whereas elderly persons account for the highest reduction in
deaths (7000).
Costs
Overall, ILI-related costswith TVP are estimated to totalmore than
$114 billion. More than 43% of costs are incurred from lost pro-
ductivity resulting from deaths, and almost 37% from inpatient
treatment of complications. Costs with UMV total more than
$111 billion, approximately $3 billion less than the cost of TVP.
Inpatient treatment and lost productivity due to deaths averted
account for the largest cost savings, at $1.7 billion and $2.2 bil-
lion, respectively.
Cost-effectiveness
In the base case, UMVdominated TVP, with UMV estimated to cost
$404 million less (excluding productivity costs) and result in al-
most 34,000 more QALYs gained than TPV.
Alternative scenarios
Tables 5 and 6 present the estimated costs and outcomes, respec-
ively, under each of the alternative scenarios. With the inclusion
f the indirect effect of vaccination, the projected cases of ILI pre-ented increased sharply, from approximately 2.4 million in the
ase case to 17 million. Hospitalizations avoided, deaths averted,
ife-years saved, and QALYs gained similarly rose, while total cost
avings increased from the base-case estimate of $3 billion to $24
illion. For all other scenarios, the number of cases and hospital-
zations avoided, deaths averted, life-years saved, QALYs gained,
nd cost savingswere lower than in the base case. Nevertheless, in
ll scenarios except that of reduced risk of ILI among unvacci-
ated, reduced risk of complications and lower vaccine effective-
ess, UMV dominated TVP (excluding cost of lost productivity). In
he “reduced ILI risk, unvaccinated” scenario, UMV cost $2800 per
ALY gained. In the “reduced complications, no MD” scenario,
MV cost $15,900 per QALY gained. In the “reduced vaccine effec-
iveness” scenario, UMV cost $8100 per QALY gained.
Sensitivity analyses
In the deterministic sensitivity analysis, the only parameter for
which varying the base-case estimate changed the results was the
percentage of high-risk individuals aged 65 years and older who
receive vaccinationwithUMV.A 25% reduction from the base-case
estimate of 83.1% coverage to 62.3% increased the ICER to $65,900
per QALY gained. When any of the other model parameters were
varied, UMV still dominated TPV.
The base case PSA resulted in UMV being dominant in 82% of
iterations, and more expensive and less effective (dominated) in
Table 4 – Predicted outcomes of UMV and TVP.
Outcome UMV
(thous)
TVP
(thous)
Difference*
(thous)
ILI cases
5 y 6781 7154 373
5–17 y 9507 10,001 494
18–49 y 26,079 26,860 782
50–64 y 9579 9878 299
65 y 8813 9283 470
Hospitalizations
5 y 28 30 2
5–17 y 38 40 2
18–49 y 268 276 8
50–64 y 321 331 10
65 y 704 744 40
Deaths
5 y 0.1 0.1 0.0
5–17 y 0.7 0.7 0.0
18–49 y 5 5 0
50–64 y 22 22 0
65 y 113 120 7
Life-years lost
5 y 3 4 1
5–17 y 19 20 1
18–49 y 135 140 5
50–64 y 498 514 16
65 y 367 388 21
QALYs lost
5 y 3 3 0
5–17 y 17 18 1
18–49 y 116 119 3
50–64 y 403 415 13
65 y 286 302 16
ILI, influenza-like illness; QALY, quality-adjusted life year; TPV, tar-
geted vaccine program; UMV, universal mass vaccination.
* A negative difference in life years and QALYs lost indicates life-
years saved and QALYs gained under UMV.no iterations. At a threshold of $50,000 per QALY gained, the net
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ents the net benefit curves of the base case and the five alternative
scenarios. In the base case, themean net benefit of 1000 iterations
was positive at all QALY threshold levels, as it was in the “inclu-
sion of indirect effect” and “lower vaccine coverage” scenarios. In
the remaining scenarios, the mean net benefit was positive above
thresholds of approximately $5000 for the “reduced ILI risk, unvac-
cinated” scenario, $20,000 for the “reduced complications, no doc-
tor visit” scenario, and $10,000 for the “reduced vaccine effective-
ness” scenario, respectively.
Discussion
Although there is substantial evidence that vaccination against
seasonal influenza in the United States is cost-saving or cost-ef-
fective in children, adults, and elderly persons [12,37–41], to the
best of our knowledge this is the first economic evaluation to con-
Table 5 – Predicted outcomes of alternative scenario
analyses.
Outcome UMV
(thous)
TVP
(thous)
Difference*
(thous)
Base-case
ILI cases 60,758 63,175 2417
Hospitalizations 1358 1421 63
Deaths 141 148 7
Life-years lost 1022 1065 43
QALYs lost 825 859 34
Inclusion of indirect effect
ILI cases 45,690 63,175 17,485
Hospitalizations 1101 1421 320
Deaths 117 148 31
Life-years lost 828 1,065 237
QALYs lost 667 859 192
Reduced ILI risk, unvaccinated
ILI cases 46,176 48,013 1,837
Hospitalizations 1032 1080 48
Deaths 107 113 6
Life-years lost 777 809 32
QALYs lost 627 652 26
Lower vaccine coverage, UMV
ILI cases 61,967 63,175 1,208
Hospitalizations 1390 1421 31
Deaths 144 148 4
Life-years lost 1044 1065 21
QALYs lost 842 859 17
Reduced complications, no
physician visit
ILI cases 60,758 63,175 2,417
Hospitalizations 847 889 42
Deaths 100 106 6
Life-years lost 600 627 27
QALYs lost 481 502 21
Reduced vaccine effectiveness
ILI cases 63,254 64,946 1,692
Hospitalizations 1461 1505 44
Deaths 155 160 5
Life-years lost 1086 1116 30
QALYs lost 875 899 24
ILI, influenza-like illness; QALY, quality-adjusted life year; TPV, tar-
geted vaccine program; UMV, universal mass vaccination.
* A negative difference in life-years and QALYs lost indicates life-
years saved and QALYs gained under UMV.sider the prospect of universal influenza vaccination in the United bStates. Our base-case analysis predicts that the likeliest outcome
of a recommendation of universal vaccination will be improved
health outcomes and lower overall costs. If true, such a result
strongly supports the case for universal recommendation. In the
probabilistic analysis derived from the base-case assumptions,
the universal recommendation dominated current policy in 82%of
iterations. If we assume QALYs were valued at a maximum of
$50,000 per additional QALY, a threshold that has been previously
used in economic evaluations of vaccination in the United States
[42], the universal recommendation results in positive net mone-
tary benefit in more than 99% of iterations.
The above probabilistic approach describes the combined im-
pact of variability around mean values of parameters such as
health care utilization or death from ILI episodes.We faced amore
fundamental level of decision uncertainty about the appropriate
values to use for five specific inputs. Therefore, we constructed
five alternative scenarios. As with the base case, probabilistic
analyses were conducted for each of these five scenarios.
The annual incidence of ILI among unvaccinated persons can-
not be predictedwith certainty. Routine surveillance is insufficient
to allow the numerator or the denominator to be determined other
than by indirectmethods requiring inference;moreover incidence
fluctuates substantially from year to year. Our analysis showed
that, all other things being equal, an estimate of ILI in the low end
of the seasonal variation, 24% lower than our base-case estimates,
resulted in cost an ICER of $24800 per QALY gained.
Another parameter value surrounded by uncertainty is vaccine
coverage following universal recommendation. We estimated
coverage by reference to another jurisdiction that has made sim-
ilar recommendations, though the transferability of these data is
questionable. In Ontario, influenza vaccine is provided at no
charge to recipients; the change in coverage resulting from expan-
sion of the vaccination policy may therefore have been greater
than would be expected in the United States. To account for this
uncertainty, we conducted an alternative analysis examining a
more conservative assumption of an increase in vaccination cov-
erage only one-half as great as that seen in Ontario after imple-
mentation of universal vaccination. Our conclusion that UMV is
cost savings remains unchanged. No costs of possible health pro-
motion were included in our analysis, but it is conceivable that
uptake could be stimulated by such campaigns. Recent qualitative
research in the United States [14] suggests that convincing the
public of the necessity of vaccination and effective communica-
tion are critical to overcome public concerns.
Vaccine effectiveness against ILI varies from year to year, de-
pending upon the match between the vaccine and the circulating
influenza strains. An alternative scenario, in which vaccine effec-
tiveness against ILI was only 70% that of our base-case estimate,
resulted in a small cost-effective ratio of less than $10,000 per
QALY gained.
It is interesting to set our population-based results alongside a
recent estimate of the economic burden of influenza in the United
States. Molinari and colleagues [3] estimated a direct medical cost
burden of $10.4 billion, and lost earnings due to illness and loss of
life of $16.3 billion. In our base case, we estimated a direct medical
cost saving of $404million fromUMV, almost 40% the total burden
of influenza estimated by Molinari et al. [3]. This discrepancy ap-
pears to be due, in large part, to differences in estimates of health
care utilization associated with influenza, with Molinari et al. [3]
redicting 334,185 influenza-attributable hospitalizations per
ear, whereas our model estimates 1.42 million hospitalizations
elated to ILI. Although substantially more ILI-related hospitaliza-
ions than hospitalizations due to serologically confirmed influ-
nza are to be expected, our model compensates for the differing
isease definitions by incorporating a lower value for vaccine ef-
ectiveness against ILI than for efficacy against influenza. Our
ase-case assumes that individualswho do not initially seek treat-
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Cost category UMV ($ millions) TVP ($ millions) Difference ($ millions)
Base case
Influenza vaccination 4562 2978 1584
Office-based physician treatment of ILI 1614 1683 69
Outpatient treatment of ILI complication 5020 5233 213
Inpatient treatment of ILI complication 40588 42282 1693
Antiviral medication 311 324 13
Lost productivity (nonfatal cases of ILI) 9865 10292 427
Lost productivity (fatal cases of ILI) 47191 49356 2165
Lost productivity (caregivers) 2261 2385 124
Total 111,412 114,531 3120
Inclusion of indirect effect
Influenza vaccination 4562 2978 1584
Office-based physician treatment of ILI 1223 1683 459
Outpatient treatment of ILI complication 3864 5233 1369
Inpatient treatment of ILI complication 32,621 42,282 9661
Antiviral medication 238 324 85
Lost productivity (nonfatal cases of ILI) 8073 10,292 2218
Lost productivity (fatal cases of ILI) 38,484 49,356 10,872
Lost productivity (caregivers) 1356 2385 1028
Total 90,422 114,531 24,109
Reduced ILI risk, unvaccinated
Influenza vaccination 4562 2978 1584
Office-based physician treatment of ILI 1227 1279 52
Outpatient treatment of ILI complication 3816 3977 162
Inpatient treatment of ILI complication 30,847 32,134 1287
Antiviral medication 236 246 10
Lost productivity (nonfatal cases of ILI) 7497 7822 325
Lost productivity (fatal cases of ILI) 35,865 37,510 1645
Lost productivity (caregivers) 1718 1812 94
Total 85,768 87,758 1991
Lower vaccine coverage, UMV
Influenza vaccination 3770 2978 792
Office-based physician treatment of ILI 1648 1683 34
Outpatient treatment of ILI complication 5127 5233 106
Inpatient treatment of ILI complication 41,435 42,282 847
Antiviral medication 317 324 6
Lost productivity (nonfatal cases of ILI) 10,078 10,292 213
Lost productivity (fatal cases of ILI) 48,273 49,356 1082
Lost productivity (caregivers) 2323 2385 62
Total 112,971 114,531 1560
Reduced complications, no physician visit
Influenza vaccination 4562 2978 1584
Office-based physician treatment of ILI 1614 1683 69
Outpatient treatment of ILI complication 2470 2583 113
Inpatient treatment of ILI complication 23,274 24,324 1050
Antiviral medication 311 324 13
Lost productivity (nonfatal cases of ILI) 7781 8124 342
Lost productivity (fatal cases of ILI) 29,634 31,094 1460
Lost productivity (caregivers) 2014 2124 110
Total 71,659 73,234 1575
Reduced vaccine effectiveness
Influenza vaccination 4562 2978 1584
Office-based physician treatment of ILI 1697 1745 48
Outpatient treatment of ILI complication 5292 5441 149
Inpatient treatment of ILI complication 43,029 44,214 1185
Antiviral medication 326 335 9
Lost productivity (nonfatal cases of ILI) 10,541 10,840 299
Lost productivity (fatal cases of ILI) 50,788 52,303 1515
Lost productivity (caregivers) 2379 2466 87
Total 118,614 120,322 1709ILI, influenza-like illness; TPV, targeted vaccine program; UMV, universal mass vaccination.
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tality as those who do, though it is possible that those who are
treated for ILI have more serious illness, and therefore higher
probability of hospitalization, than thosewhodonot. In sensitivity
analysis we explored an alternative scenario that assumed that
thosewith no initial physician visit did not develop complications.
This scenario resulted in an ICER of $15,900 per QALY gained for
UMV compared with TVP. The discrepancy between our estimates
of ILI-related hospitalizations and those of Molinari et al. [3] re-
garding estimates of influenza-attributable hospitalizations may
require further study.
Our base-case analysis did not include potential indirect ef-
fects of vaccination arising from herd immunity, for conservative-
ness. As would be expected, inclusion of such effects substantially
increased themodeled health benefits. This points theway toward
Fig. 3 – Net benefit curves, baspotential further research, because there may well be a quantifi-able relationship between the level of investment in promotion of
vaccination and its overall cost-effectiveness, mediated through
the effect of promotion on coverage, which in turn would drive
herd immunity. In the absence of an indirect effect, promoting
vaccination would be expected to show diminishing marginal re-
turns, but if herd immunity is considered its benefits may offset
such a diminution.
The incremental cost per QALY gained is a conventionalmetric
for economic evaluations and, being a ratio, is independent of the
size of the population studied. Decision makers may also wish to
understand the overall economic value of a universal vaccination
program to theUS population, in the context of previous estimates
of the economic burden of influenza to the United States. This can
be estimated by combining the population costs of vaccination
with the savings due to reductions in use of resources to treat
se, and alternative scenarios.e cainfluenza complications and reductions in productivity losses,
810 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 8 0 0 – 8 1 1along with a monetary valuation of survival and quality of life.
Assuming each additional QALY is valued at $50,000, our base-
case estimate of the netmonetary benefit of universal vaccination
to US society ismore than $2 billion, with a 95% credibility interval
of $563 million to $3.7 billion. If we replace our base-case assump-
tions in turn with the pessimistic scenarios, in which vaccination
uptake rates are lower than predicted, the ILI incidence lies at the
lower extreme, complications do not occur among persons who
are not treated for ILI, and vaccination is assumed to be rather less
effective, the point estimates of net benefit would bemoremodest
at $939 million, $1.193 billion, $698 million and $960 million, re-
spectively. The scenario that includes the indirect benefit of vac-
cination leads to a net benefit estimate of over $19 billion, some 10
times greater than the base case.
The economic analyses follow US recommendations by ex-
cluding the cost of productivity changes from total costs entering
into cost-effectiveness ratios (or net monetary benefit calcula-
tions), for the reason that these should already be accounted for in
the valuation of life expectancy. Nonetheless, an important find-
ing is that themajority of the projected cost savings are accounted
for by lost productivity, mostly due to mortality but also due to
morbidity fromcomplications and caregiver time. In the base case,
the total cost savings are estimated at $3 billion, or 2.7% of the total
costs of influenza under TVP. The savings when productivity
changes are ignored amount to only $400million, yet these are still
sufficient to make a strong case for the economic value of UMV.
This study has a number of limitations, most of which relate to
uncertainty around the modeling assumptions. We have at-
tempted to address these through probabilistic sensitivity analy-
ses applied to a base case and five scenario analyses. Nevertheless,
the discrepancy between our estimates of hospitalizations associ-
ated with ILI and estimates of hospitalizations from influenza
from a previous study merits further investigation. Our estimates
of ILI among vaccinated individuals were derived by multiplying
the probability of ILI among unvaccinated by the reduction in ILI
due to vaccine effectiveness, and do not account for the fact that
some people may have been vaccinated after developing ILI; ILI
among vaccinated persons in a real-world setting may therefore
be higher than our estimates.
Our estimates of the indirect benefit via herd immunity are
conservative in that they consider only the effect of increased
childhood vaccination on the probability of ILI, and do not take
into account reductions in ILI that may result from increased cov-
erage among adults. Nevertheless, the inclusion of herd effect has
a dramatic impact on the results in favor of UMV. It is also possible
that our estimates of the reduction in ILI due to increased coverage
in children, whichwere derived from a data simulation,may over-
estimate the true impact in a real world setting.
Finally, we conducted the probabilistic sensitivity analysis
with the assumption of independence of age-specific parameter
estimates. To the extent that this assumption is not correct, the
uncertainty surrounding the parameters is misspecified. It is un-
clear if this assumption results in an under- or overestimate of the
model uncertainty.
Conclusions
Under a wide range of plausible assumptions, universal vaccina-
tion of the US population against seasonal influenza is likely be-
yond reasonable doubt to be cost-effective, given a conservative
valuation of quality-adjusted survival gains. UMV may well meet
the stricter criterion of producing net cost savings to US society,
without consideration of health gain arising from reduced influ-
enza morbidity and mortality. Therefore, our results support the
recent Advisory Committee on Immunization Practices position in
favor of universal vaccination.Acknowledgment
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